High-Risk Neuroblastoma: Current and Future Therapeutic Strategies - Abstract
High-risk neuroblastoma remains a significant treatment challenge. Currently, less than half of patients survive, despite intensive multi-agent, multimodal therapies. We give an overview of the current treatment strategy and summarize the evidence for this approach, before discussing options for treatment of refractory and relapsed disease. Finally, we discuss significant international collaborative efforts to improve treatment by specifically targeting the key genetic drivers of neuroblastoma to positively impact on survival.